EGFR-targeted TKI
|
BT-549-EV
|
BT-549-A6sh
|
Fold change EV:A6sh
|
P-value EV:A6sh
|
---|
PD153035
| 6.46 ± 0.62 | 4.16 ± 0.12 | 1.55 | 0.02* |
Lapatinib
| 14.09 ± 1.75 | 5.99 ± 1.77 | 2.35 | 0.03* |
Canertinib
| 4.30 ± 0.24 | 3.96 ± 0.11 | 1.09 | 0.10 |
Gefitinib
| 14.43 ± 0.71 | 13.51 ± 2.83 | 1.07 | 0.80 |
- IC50 - half maximal inhibitory concentration (μM) estimated from the regression plots for the indicated tyrosine kinase inhibitors (TKI). BT-549-EV, control BT-549 cells; BT-549-A6sh, AnxA6-depleted BT-549 cells. For fold change and p-values, EV: A6sh denotes, BT-549 control cells versus AnxA6-depleted cells. *Statistically significant at p < 0.05.